Latest Breaking News On - Lymphoma myeloma - Page 1 : vimarsana.com

The Fludarabine Shortage and Its Ripple Effects: Navigating the Crisis

The significant surge in oncology drug shortages in 2023 particularly affected essential chemotherapeutic drugs.

United statesUniversity of southern californiaLos angelesJose tinajeroTeny khachadourianisTammy harutunyanisAamir aliMichaela maherisColl clin pharmAlfrede mann school of pharmacyAmerican society for transplantationAmerican society of healthHematology oncology pharmacy associationCity of hope national medical centerSciences in los angelesNorris comprehensive cancer center

Assessing Philadelphia-Like B-Cell ALL in a Largely Hispanic Population

Ph-like ALL may be predominantly prevalent in Hispanic and Latino populations.

Los angelesUnited statesSan diegoUniversity of southern californiaZyanya rizzoMelissa martinezAamir aliMaryam saheb kashafAmerican society of hematology annual meeting expositionCity of hope national medical centerSciences in los angelesNorris comprehensive cancer centerUniversity of texas md anderson cancer centerAlfrede mann school of pharmacyPh likeb cellCancer center

Developing point-of-care CAR T manufacturing

Developing point-of-care CAR T manufacturing
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Israel generalHebrew universityArnon naglerDrug administrationAccreditation committeeOncology centerEuropean haematology associationSheba medical centerHadassah medical schoolInternational bloodInternational blood marrow transplant researchCord blood bankMarrow transplant researchDivision of hematologyEuropean society for bloodIta university

Real-World Data Show Oral Decitabine/Cedazuridine Regimen Is Comparable With IV/SC HMAs in MDS

Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs.

United statesNew havenSamer zeidanDaiichi sankyoStates cerner envizaBoehringer ingelheim incyteMyeloid malignancies at yale cancer centerEarly therapeutics researchClinical research team for leukemiasAmerican society of hematologyAnnual meetingClinical research teamMyeloid malignanciesYale cancer centerEnd resultsUnited states cerner enviza

DARZALEX® (daratumumab) Subcutaneous Formulation-Based

DARZALEX® (daratumumab) Subcutaneous Formulation-Based
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesRegion flamandeCraig tendlerEuropean myeloma networkJanssen pharmaceutical companies of johnsonJanssen researchGlobal medical affairsExchange commissionJanssen biotech incAmerican society of hematologyEuropean medicines agencyEuropean unionJanssen research developmentCompanies of johnsonSlate development